🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎯 Target of the week: Stimulator of interferon genes protein, encoded by the #STING1 gene. Explore this antibody characterization report, generated using our standardized characterization procedure. report➡️doi.org/10.5281/zenodo… procedure ➡️doi.org/10.21203/rs.3.…

🎯Target of the week: Protein-glutamine gamma-glutamyltransferase 2 (TGM2). Characterization data for 17 TGM2 antibodies was published to F1000Research in an open and transparent manner promotes the use of reliable research tools for this target ➡️doi.org/10.12688/f1000…

📢 Happy to announce the antibody validation data for S1PR1 is now also published to our F1000Research gateway. ➡️doi.org/10.12688/f1000… #S1PR1 #antibodycharacterization #reproducibleresearch

🎯Target of the week: Synaptotagmin-1. We are pleased to share this publication as it marks the first target for which we have included flow cytometry to our procedure ➡️doi.org/10.12688/f1000…

Special thank you to those involved at the OnlyGoodAntibodies and University of Leicester for piloting the addition of flow cyt to our platform and for your unwavering dedication to increasing accessibility of reproducible data.

Thank you YCharOS for letting us join the antibody characterisation party! We found some great tools to study SYT-1 by flow

2 comprehensive #OpenScience reports by YCharOS which empower users to make informed decisions when selecting the most suitable antibody for their specific needs. 1. Sequestosome-1: f1000research.com/articles/12-32… 2. Midkine: f1000research.com/articles/12-14…

Quality reagents equals quality and reproducible science. A piece on the antibody situation by Rick Kahn and colleagues. elifesciences.org/articles/100211

Congrats to all co-authors on this eLife - the journal publication! Looking at the history of the antibody characterization crisis, highlighting challenges, best practices, and the need for stakeholder action🎉👏👏 #AntibodyValidation #ReproducibleResearch ➡️doi.org/10.7554/eLife.…

🎯Target of the week: Huntingtin Excited to share our latest publication, providing researchers with access to high-quality antibodies to accelerate Huntington’s Disease research. ➡️doi.org/10.12688/f1000… #HTT #openscience #reproducibility

Rachel Harding and YCharOS characterized 20 #Huntingtin commercial #antibodies empowering users to make informed decisions when selecting high-quality reagents to accelerate #HuntingtonDisease research. ▶ f1000research.com/articles/13-92…

An important article reviewing the history of the antibody characterization crisis by documenting efforts and initiatives, such as YCharOS, to address the problem, focusing on antibodies that target human proteins.  Read more: elifesciences.org/articles/10021…

🎉Celebrating a new milestone: Over 100 antibody characterization reports #openly available on our Zenodo community, with several converted to peer-reviewed F1000 publications! ➡️zenodo.org/communities/yc… ➡️f1000research.com/gateways/ychar…

🎯Target of the week: CSNK2A1 Be sure to check out this publication on F1000Research as many successful #antibodies can be identified across all three antibody-based applications. The future of #CSNK2A1 research looks promising! #openscience ➡️doi.org/10.12688/f1000…

So great to connect with our partner DSHB at SFN!

Thrilled to see our own Carl Laflamme and Riham Ayoubi featured in this Nature article for their fantastic antibody characterization work!

We are humbled by the support of CQDM for our work at McGill University furthering antibody characterization!